These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

558 related items for PubMed ID: 12789266

  • 1. Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1.
    DuHadaway JB, Du W, Donover S, Baker J, Liu AX, Sharp DM, Muller AJ, Prendergast GC.
    Oncogene; 2003 Jun 05; 22(23):3578-88. PubMed ID: 12789266
    [Abstract] [Full Text] [Related]

  • 2. The c-Myc-interacting adaptor protein Bin1 activates a caspase-independent cell death program.
    Elliott K, Ge K, Du W, Prendergast GC.
    Oncogene; 2000 Sep 28; 19(41):4669-84. PubMed ID: 11032017
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB, Omer CA, Abrams MT, Bhimnathwala HG, Brucker MJ, Buser CA, Davide JP, deSolms SJ, Dinsmore CJ, Ellis-Hutchings MS, Kral AM, Liu D, Lumma WC, Machotka SV, Rands E, Williams TM, Graham SL, Hartman GD, Oliff AI, Heimbrook DC, Kohl NE.
    Cancer Res; 2001 Dec 15; 61(24):8758-68. PubMed ID: 11751396
    [Abstract] [Full Text] [Related]

  • 4. Adenovirus E1A oncoprotein liberates c-Myc activity to promote cell proliferation through abating Bin1 expression via an Rb/E2F1-dependent mechanism.
    Kinney EL, Tanida S, Rodrigue AA, Johnson JK, Tompkins VS, Sakamuro D.
    J Cell Physiol; 2008 Sep 15; 216(3):621-31. PubMed ID: 18348166
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The farnesyltransferase inhibitor, FTI-2153, inhibits bipolar spindle formation during mitosis independently of transformation and Ras and p53 mutation status.
    Crespo NC, Delarue F, Ohkanda J, Carrico D, Hamilton AD, Sebti SM.
    Cell Death Differ; 2002 Jul 15; 9(7):702-9. PubMed ID: 12058275
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
    Lerner EC, Zhang TT, Knowles DB, Qian Y, Hamilton AD, Sebti SM.
    Oncogene; 1997 Sep 15; 15(11):1283-8. PubMed ID: 9315095
    [Abstract] [Full Text] [Related]

  • 8. Farnesyltransferase inhibitors reverse Ras-mediated inhibition of Fas gene expression.
    Zhang B, Prendergast GC, Fenton RG.
    Cancer Res; 2002 Jan 15; 62(2):450-8. PubMed ID: 11809695
    [Abstract] [Full Text] [Related]

  • 9. Bin1 functionally interacts with Myc and inhibits cell proliferation via multiple mechanisms.
    Elliott K, Sakamuro D, Basu A, Du W, Wunner W, Staller P, Gaubatz S, Zhang H, Prochownik E, Eilers M, Prendergast GC.
    Oncogene; 1999 Jun 17; 18(24):3564-73. PubMed ID: 10380878
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
    Sun J, Qian Y, Hamilton AD, Sebti SM.
    Oncogene; 1998 Mar 17; 16(11):1467-73. PubMed ID: 9525745
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Non-Ras targets of farnesyltransferase inhibitors: focus on Rho.
    Lebowitz PF, Prendergast GC.
    Oncogene; 1998 Sep 17; 17(11 Reviews):1439-45. PubMed ID: 9779989
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Inhibition of farnesyltransferase increases TGFbeta type II receptor expression and enhances the responsiveness of human cancer cells to TGFbeta.
    Adnane J, Bizouarn FA, Chen Z, Ohkanda J, Hamilton AD, Munoz-Antonia T, Sebti SM.
    Oncogene; 2000 Nov 16; 19(48):5525-33. PubMed ID: 11114730
    [Abstract] [Full Text] [Related]

  • 16. Geranylgeranylated, but not farnesylated, RhoB suppresses Ras transformation of NIH-3T3 cells.
    Mazières J, Tillement V, Allal C, Clanet C, Bobin L, Chen Z, Sebti SM, Favre G, Pradines A.
    Exp Cell Res; 2005 Apr 01; 304(2):354-64. PubMed ID: 15748883
    [Abstract] [Full Text] [Related]

  • 17. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB.
    Du W, Lebowitz PF, Prendergast GC.
    Mol Cell Biol; 1999 Mar 01; 19(3):1831-40. PubMed ID: 10022870
    [Abstract] [Full Text] [Related]

  • 18. Role for RhoB and PRK in the suppression of epithelial cell transformation by farnesyltransferase inhibitors.
    Zeng PY, Rane N, Du W, Chintapalli J, Prendergast GC.
    Oncogene; 2003 Feb 27; 22(8):1124-34. PubMed ID: 12606940
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.